| Literature DB >> 29559964 |
Josselin Bodilis1,2, Elodie Denet1, Elisabeth Brothier1, Arnault Graindorge1, Sabine Favre-Bonté1, Sylvie Nazaret1.
Abstract
The Burkholderia cenocepacia epidemic ET12 lineage belongs to the genomovar IIIA including the reference strain J2315, a highly transmissible epidemic B. cenocepacia lineage. Members of this lineage are able to cause lung infections in immunocompromised and cystic fibrosis patients. In this study, we describe the genome of F01, an environmental B. cenocepacia strain isolated from soil in Burkina Faso that is, to our knowledge, the most closely related strain to this epidemic lineage. A comparative genomic analysis was performed on this new isolate, in association with five clinical and one environmental B. cenocepacia strains whose genomes were previously sequenced. Antibiotic resistances, virulence phenotype, and genomic contents were compared and discussed with an emphasis on virulent and antibiotic determinants. Surprisingly, no significant differences in antibiotic resistance and virulence were found between clinical and environmental strains, while the most important genomic differences were related to the number of prophages identified in their genomes. The ET12 lineage strains showed a noticeable greater number of prophages (partial or full-length), especially compared to the phylogenetically related environmental F01 strain (i.e., 5-6 and 3 prophages, respectively). Data obtained suggest possible involvements of prophages in the clinical success of opportunistic pathogens.Entities:
Keywords: Burkholderia cenocepacia; Burkina Faso; RND pumps; antibiotic resistance; prophages; virulence factors
Year: 2018 PMID: 29559964 PMCID: PMC5845691 DOI: 10.3389/fmicb.2018.00383
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
General genomic features of the studied B. cenocepacia strains.
| F01 | J2315 | BC7 | K56-2 | H111 | MC0-3 | AU 1054 | |
|---|---|---|---|---|---|---|---|
| Source | Soil | Clinical (CF isolate) | Clinical (CF isolate) | Clinical (CF isolate) | Clinical (CF isolate) | maize rhizosphere | Clinical (CF) |
| Location | Burkina Faso (Ouagadougou) | United Kingdom (Edinburgh) | Canada | Canada | Germany (Hannover) | United States (Michigan) | United States |
| Reference | This study | Unpublished | Unpublished | ||||
| Genbank Accesion Number | GCA000009485.1 | ALIZ00000000.2 | ASM98130.1 | ASM23621.4 | ASM1950.1 | ASM1408.1 | |
| Genome size (bp) | 8,041,553 | 8,055,782 | 7,991,017 | 7,752,055 | 7,684,399 | 7,971,389 | 7,279,116 |
| # Chromosomes | NA | 3 | NA | NA | NA | 3 | 3 |
| # Plasmids | NA | 1 | NA | NA | NA | 0 | 0 |
| # Contigs | 91 | NA | 295 | 19 | 71 | NA | NA |
| G+C (%) | 67.2 | 66.9 | 66.8 | 67.0 | 67.4 | 66.6 | 66.9 |
| Average CDS length (bp) | 906.5 | 931.0 | 910,3 | 938,6 | 953,5 | 935.7 | 945.9 |
| Coding density (%) | 88.7 | 86.9 | 87,4 | 87,7 | 88,2 | 87.7 | 87.5 |
| # CDSs | 8,185 | 7,871 | 7,846 | 7,391 | 7,204 | 7,697 | 6,961 |
| # Ribosomal RNA operons | NA | 6 | NA | NA | NA | 6 | 6 |
| # Transfer RNA genes | 59 | 74 | 69 | 67 | 59 | 67 | 67 |
| # Putative prophage islands (# full-length propages) | 3 (2) | 6 (4) | 6 (4) | 5 (3) | 3 (3) | 4 (1) | 1 (1) |
| # Strain-specific CDSs | 1463 | 139 | 391 | 144 | 599 | 1176 | 760 |
Putative prophage islands (PI) identified in the studied B. cenocepacia strains.
| Prophage-like islanda | Strain | ORFs | Size (kb) | # ORFS | Homolog prophage among the other studied strains (% of conserved genes)b | Closest homolog with previously descripted phage (% of conserved genes) | Descriptionc |
|---|---|---|---|---|---|---|---|
| PI_J2315_1 | J2315 | BCAL0081-BCAL0107 | 24.9 | 27 | PI_BC7_4 (100%) | phiE202 (50.0%) | Putative prophage |
| PI_J2315_2 | J2315 | BCAL1559-BCAL1606 | 37.3 | 49 | PI_BC7_6 (100%) | KS10 (100%) | |
| PI_J2315_3 | J2315 | BCAM1024-BCAM1096 | 46.8 | 76 | PI_BC7_2 (100%) | SEN34 (26.3%) | Putative prophage |
| PI_J2315_4 | J2315 | BCAM0001AM_1973-BCAM0001AM_2038 | 46.3 | 71 | PI_BC7_3 (100%) | No homolog | Prophage-like |
| PI_J2315_5 | J2315 | BCAS0504-BCAS0554 | 37.2 | 52 | PI_BC7_5 (100%) | BcepMu (98.1%) | |
| PI_J2315_6 | J2315 | BCAL2961-BCAL2972 | 13.9 | 20 | PI_BC7_1 (100%) | No homolog | Prophage-like |
| PI_BC7_1 | BC7 | ALIZ_v1_240021-ALIZ_v1_240040 | 13.9 | 20 | PI_J2315_6 (100%) | No homolog | Prophage-like |
| PI_BC7_2 | BC7 | ALIZ_v1_310024-ALIZ_v1_310099 | 46.8 | 76 | PI_J2315_3 (100%) | SEN34 (26.3%) | Putative prophage |
| PI_BC7_3 | BC7 | ALIZ_v1_870050-ALIZ_v1_1440021 | 46.3 | 71 | PI_J2315_4 (100%) | No homolog | Prophage-like |
| PI_BC7_4 | BC7 | ALIZ_v1_1010011-ALIZ_v1_1550014 | 24.9 | 27 | PI_J2315_1 (100%) | phiE202 (50.0%) | Putative prophage |
| PI_BC7_5 | BC7 | ALIZ_v1_1830002-ALIZ_v1_1830053 | 37.2 | 52 | PI_J2315_5 (100%) | BcepMu (98.1%) | |
| PI_BC7_6 | BC7 | ALIZ_v1_2510102-ALIZ_v1_2510150 | 37.3 | 49 | PI_J2315_2 (100%) | KS10 (100%) | |
| PI_K56-2_1 | K56-2 | ALJA_v1_70123-ALJA_v1_70152 | 24.9 | 27 | PI_J2315_1 (100%) | phiE202 (50.5%) | Putative prophage |
| PI_K56-2_2 | K56-2 | ALJA_v1_80531-ALJA_v1_80608 | 44.0 | 78 | PI_J2315_3 (98.6%) | SEN34 (25.6%) | Putative prophage |
| PI_K56-2_3 | K56-2 | ALJA_v1_81440-ALJA_v1_81501 | 45.8 | 62 | PI_J2315_4 (87.3%) | No homolog | Prophage-like |
| PI_K56-2_4 | K56-2 | ALJA_v1_120326-ALJA_v1_120375 | 37.3 | 49 | PI_J2315_2 (98%) | KS10 (100%) | |
| PI_K56-2_5 | K56-2 | ALJA_v1_150265-ALJA_v1_150285 | 13.9 | 21 | PI_J2315_6 (95.2%) | No homolog | Prophage-like |
| PI_F01_1 | F01 | F01_v2_10038-F01_v2_10052 | 13.4 | 15 | PI_MC0-3_1 (20.0%) | phiE125 (7.0%) | Prophage-like |
| PI_F01_2 | F01 | F01_v2_50119-F01_v2_50190 | 68.9 | 72 | PI_MC0-3_1 (41.7%) | KL3 (48.6%) | Putative prophage |
| PI_F01_3 | F01 | F01_v2_230115-F01_v2_230168 | 42.8 | 56 | No homolog | BcepC6B (71.4%) | Putative prophage |
| PI_H111_1 | H111 | CAFQ_v1_150037-CAFQ_v1_150122 | 36.0 | 85 | No homolog | JBD44 (16.4%) | Putative prophage |
| PI_H111_2 | H111 | CAFQ_v1_320028-CAFQ_v1_320058 | 38.8 | 31 | PI_J2315_1 (83.9%) | KL3 (48.1%) | Putative prophage |
| PI_H111_3 | H111 | CAFQ_v1_430147-CAFQ_v1_430193 | 10.8 | 47 | No homolog | phiH111-1 | |
| PI_MC0-3_1 | MC0-3 | Bcenmc03_0165-Bcenmc03_0214 | 38.8 | 50 | PI_F01_2 (41.7%) | KS5 (70.0%) | Putative prophage |
| PI_MC0-3_2 | MC0-3 | Bcenmc03_1281-Bcenmc03_1291 | 10.8 | 11 | No homolog | phi2 (7.7%) | Prophage-like |
| PI_MC0-3_3 | MC0-3 | Bcenmc03_6783-Bcenmc03_6787 | 10.0 | 12 | No homolog | No homolog | Prophage-like |
| PI_MC0-3_4 | MC0-3 | Bcenmc03_4251-Bcenmc03_4256 | 4.3 | 8 | No homolog | No homolog | Prophage-like |
| PI_AU1054_1 | AU 1054 | Bcen_4855-Bcen_4870 | 12.2 | 19 | No homolog | No homolog | Prophage-like |
Antibiotic resistances of seven studied B. cenocepacia strains.
| Drug | Class | J2315 | BC7 | K56-2 | F01 | H111 | MC0-3 | AU1054 |
|---|---|---|---|---|---|---|---|---|
| Piperacillin + tazobactam | Penicillin | Sa | S | I | S | S | R | S |
| Ticarcillin | Penicillin | R | R | R | R | R | R | R |
| Ticarcillin + clavulanic acid | Penicillin | R | R | R | R | R | R | R |
| Imipenem | Carbapenem | R | R | R | R | R | S | R |
| Meropenem | Carbapenem | S | I | I | S | I | S | S |
| Cefepime | Cephalosporin | S | S | R | S | R | R | R |
| Cefpirome | Cephalosporin | R | R | R | R | R | R | R |
| Ceftazidime | Cephalosporin | S | S | S | S | S | S | R |
| Chloramphenicol | Phenicol | S | S | S | S | S | S | R |
| Minocycline | Tetracylcine | S | S | S | S | S | S | S |
| Colistin | Polymyxin | R | R | R | R | R | R | R |
| Tripmethoprim + sulfamethoxazole | Sulfamide-Trimethoprim | I | S | S | S | S | S | R |
| Ciprofloxacin | Fluoroquinolone | R | S | R | R | R | R | R |
| Levofloxacin | Fluoroquinolone | I | S | R | I | S | I | R |
| Ofloxacin | Fluoroquinolone | R | R | R | R | R | R | R |
| Pefloxacin | Fluoroquinolone | R | S | I | R | I | R | R |